In conclusion, the results from this study support the therapeutic potential of dual inhibition of AXL and SRC towards KRAS mutant NSCLC therapies and will aid in our understanding of molecular mechanisms behind TKI therapies in KRAS mutant harboring cancers. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.